A Brief History of Global Blood Therapeutics, Inc. (GBT)

Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics to treat blood-based disorders. The company was founded in 2011 and is headquartered in South San Francisco, California.

• 2011: GBT was founded by Matthew P. Jacobson, Charles J. Homcy, and Ted W. Love with the goal of addressing unmet medical needs in the field of blood disorders.
• 2015: GBT went public with an initial public offering (IPO) on the NASDAQ stock exchange, raising funds to support the development of its lead drug candidate for sickle cell disease.
• 2017: The U.S. Food and Drug Administration (FDA) granted GBT's lead drug candidate, voxelotor (Oxbryta), Breakthrough Therapy designation for the treatment of sickle cell disease.
• 2019: GBT received FDA approval for Oxbryta for the treatment of sickle cell disease in adults and children 12 years of age and older. This marked a major milestone for the company and provided a new treatment option for patients with this serious and life-threatening genetic disorder.
• 2021: GBT continues to advance its pipeline of potential therapies for blood disorders, including ongoing clinical trials for sickle cell disease and other conditions. The company remains committed to making a meaningful difference in the lives of patients worldwide.

Who Owns Global Blood Therapeutics, Inc. (GBT)

Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical company focused on developing drugs for the treatment of severe blood disorders. The company was founded in 2011 by CEO Ted W. Love, M.D., who currently leads the company in its mission to address unmet medical needs in the field of hematology.

As of the most recent data available, institutional investors own the majority of Global Blood Therapeutics, Inc. These investors include large financial institutions, mutual funds, and hedge funds that hold significant stakes in the company. Some of the top institutional investors in GBT include Vanguard Group, BlackRock, and Fidelity Investments.

In addition to institutional investors, individual insiders also own a significant portion of GBT. This includes members of the company's management team, board of directors, and other key employees who have acquired shares in the company as part of their compensation packages.

• Ted W. Love, M.D. - CEO and founder of Global Blood Therapeutics, Inc.
• Various institutional investors - Including Vanguard Group, BlackRock, and Fidelity Investments
• Individual insiders - Members of the company's management team, board of directors, and key employees

Global Blood Therapeutics, Inc. (GBT) Mission Statement

Global Blood Therapeutics, Inc. (GBT) is committed to transforming the treatment and care of individuals living with sickle cell disease (SCD). Our mission is to discover, develop, and deliver innovative therapies that address the underlying biochemical pathways of SCD to provide meaningful improvements in patient outcomes.

At GBT, we believe that no individual should have to endure the debilitating effects of SCD. Our focus is on developing novel treatment options that have the potential to significantly impact the lives of those affected by this devastating disease.

• Advance Research: We are dedicated to advancing scientific research and understanding of SCD to identify new treatment approaches.
• Develop Innovative Therapies: We are committed to developing innovative therapies that target the root cause of SCD to improve patient outcomes.
• Improve Patient Care: We strive to improve the lives of individuals living with SCD by providing access to cutting-edge treatments and comprehensive care.

How Global Blood Therapeutics, Inc. (GBT) Works

Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical company that is dedicated to discovering, developing, and commercializing novel therapeutics to treat blood-based disorders. The company focuses on developing innovative treatments for patients with sickle cell disease, a genetic blood disorder that affects hemoglobin in red blood cells.

GBT works by leveraging its deep understanding of the molecular mechanisms underlying blood disorders to develop potential therapies. The company's research and development efforts are centered around its lead product candidate, voxelotor, which is designed to inhibit sickle hemoglobin polymerization and improve red blood cell deformability.

GBT collaborates with healthcare providers, patients, and advocacy groups to better understand the unmet needs of individuals living with sickle cell disease. By engaging with stakeholders in the sickle cell community, the company can tailor its research and development efforts to address specific challenges faced by patients.

Furthermore, GBT works closely with regulatory authorities to navigate the complex drug development and approval process. The company conducts clinical trials to evaluate the safety and efficacy of its therapies and seeks regulatory approval to bring its treatments to market.

• Research and Development: GBT conducts research to uncover novel therapeutic targets and mechanisms of action for treating blood disorders.
• Collaboration: The company collaborates with healthcare providers, patients, and advocacy groups to ensure its therapies meet the needs of the sickle cell community.
• Clinical Trials: GBT conducts clinical trials to evaluate the safety and efficacy of its lead product candidate, voxelotor, in patients with sickle cell disease.
• Regulatory Approval: GBT seeks regulatory approval to commercialize its therapies and make them available to patients in need.

How Global Blood Therapeutics, Inc. (GBT) Makes Money

Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical company that focuses on the development and commercialization of innovative treatments for blood disorders. The company generates revenue through the following key avenues:

• Product Sales: GBT generates revenue through the sale of its flagship product, Oxbryta (voxelotor). Oxbryta is the first approved treatment for sickle cell disease that specifically targets the root cause of the disease by inhibiting sickle hemoglobin polymerization.
• Licensing Agreements: GBT enters into licensing agreements with other pharmaceutical companies for the development, commercialization, and distribution of its products. These agreements often involve upfront payments, milestone payments, and royalties on sales.
• Clinical Trials: GBT conducts clinical trials to test the safety and efficacy of its investigational products. The company collaborates with research institutions, healthcare providers, and contract research organizations to conduct these trials, generating revenue through grants, contracts, and collaborations.
• Partnerships and Collaborations: GBT forms partnerships and collaborations with other biopharmaceutical companies, academic institutions, and healthcare organizations to advance its research and development efforts. These collaborations often involve upfront payments, milestone payments, and shared development costs and revenues.